Building IND-Ready and Investor-Ready Development Programs On-Demand Webinar Building IND-Ready and Investor-Ready Development Programs Learn how emerging biotechs can build IND-ready, investor-ready development programs using Totality of Evidence, NAMs,…CertaraJune 15, 2026
Data, models, and modalities: Key themes from the Certainty 2026 Discovery UGM Blog Data, models, and modalities: Key themes from the Certainty 2026 Discovery UGM A recap of the Certainty 2026 Discovery UGM in Boston, covering the top themes from…CertaraJune 15, 2026
2026 Simcyp Workshops Brochure 2026 Simcyp Workshops Advance your PBPK and model-informed drug development expertise with Simcyp workshops. Learn from experts through…CertaraJune 11, 2026
QSP modeling for Parkinson’s disease: Solving the synthetic control challenge in clinical trials Blog QSP modeling for Parkinson’s disease: Solving the synthetic control challenge in clinical trials QSP modeling for Parkinson’s disease tackles optimized standard-of-care, placebo response, and missing biomarkers. See how…CertaraJune 11, 2026
Mechanistic MIDD: Achieving Regulatory Success Through Strong Scientific Foundations Live Events Mechanistic MIDD: Achieving Regulatory Success Through Strong Scientific Foundations June 30, 2026 - 12:00 PM – 2:00 PMCertaraJune 10, 2026
Model Smarter, Not Harder: Introducing Model Designer On-Demand Webinar Model Smarter, Not Harder: Introducing Model Designer Watch Model Designer on demand: Certara's browser based tool for faster NLME model discovery, configuration,…CertaraJune 10, 2026
Population Pharmacokinetic Modeling to Predict Absorbed and Biologically Effective Dose for Radioligand Therapies Poster Population Pharmacokinetic Modeling to Predict Absorbed and Biologically Effective Dose for Radioligand Therapies Explore how population PK modeling predicts absorbed dose and biologically effective dose for radioligand therapies.CertaraJune 9, 2026
The Case for Simulating Pregnancy Press Coverage The Case for Simulating Pregnancy Pregnant women are routinely excluded from drug trials, leaving clinicians without dosing guidance. Discover how…CertaraJune 9, 2026
Clinical Validation of a QSP Model for ISB 2001, a Trispecific T Cell Engager to Support Optimal FIH Study Design in RRMM Patients Publication Clinical Validation of a QSP Model for ISB 2001, a Trispecific T Cell Engager to Support Optimal FIH Study Design in RRMM Patients See how a QSP model guided efficacy-proximal FIH dosing for ISB 2001 in the TRIgnite-1…CertaraJune 4, 2026
Applying AI-Driven Biosimulation to Drug Discovery Video Applying AI-Driven Biosimulation to Drug Discovery Certara President Leif Pedersen explains how PBPK and QSP modeling, proven across 125+ FDA-approved drugs,…CertaraJune 2, 2026